Patents
Sitemap › C07 - Organic chemistry › C07C - Acyclic or carbocyclic compounds › C07C 401 - Irradiation products of cholesterol or its derivatives; Vitamin d derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
Patents for C07C 401 - Irradiation products of cholesterol or its derivatives; Vitamin d derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation (3,426)
01/2008
01/30/2008CN100364969C Water soluble vitamins D2 preparation method
01/29/2008US7323580 Crystals of a vitamin D derivative and a method for the preparation thereof
01/17/2008US20080014642 Tagging reagents and methods for hydroxylated compounds
01/16/2008EP1877063A2 19,26,27-trinor-1alpha ,25-dihydroxyvitamin d3 compounds
01/03/2008WO2007118198A3 2-METHYLENE-1α,25-DIHYDROXY-19,21-DINORVITAMIN D3 ANALOGS AND USES THEREOF
01/02/2008EP1871386A1 Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin d compounds or mimics thereof
01/02/2008CN101096354A Method for oriented synthesis of unsaturated conjugated alcohol
12/2007
12/19/2007EP1865965A1 2-methylene-19-nor-(23s)-25-dehydro-1 -hydroxyvitamin d3-26,23-lactone and 2-methylene-19-nor-(23r)-25-dehydro-1 -hydroxyvitamin d3-26,23-lactone
12/13/2007WO2007142158A1 9,10-secopregnane derivative and pharmaceutical
12/13/2007CA2653772A1 9,10-secopregnane derivative and pharmaceutical
12/12/2007CN101085755A Actinic chemistry reaction device and method for synthesizing provitamin D3
12/06/2007CA2667854A1 Tagging reagents and methods for hydroxylated compounds
11/2007
11/29/2007WO2007117563A3 1.alpha.-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and use thereof
11/27/2007US7300925 treating psoriasis with e.g. 19-nor-2beta-ethyl-1alpha,25-dihydroxyvitamin D3
11/22/2007WO2007131364A1 Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
11/22/2007WO2006057886A8 2-METHYLENE-19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND ITS USES
11/22/2007US20070270391 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses
11/20/2007CA2140382C Vitamin d compounds and method of preparing these compounds
11/15/2007US20070265233 Arginine Heteromers for Topical Administration
11/14/2007EP1853274A2 2-methylene-19-nor- (20s-24s) - 1alpha, 25-d hydroxyvitamine-d2
11/08/2007US20070259838 17,20(Z)-Dehydro Vitamin D Analogs and Their Uses
11/07/2007CN101068779A 9,10-secopregnane derivative and medicine
11/07/2007CN101068778A Preparation of 3-[5'-(3,4-bis(hydroxymethyl)benzyloxy)-2'-ethyl-2-propylbiphenyl-4-yl]pentan-3-ol
11/07/2007CN100347156C Vitamin D separating, purifying and crystallizing method
11/01/2007US20070255066 Epimerisation of Allylic Alcohols
11/01/2007US20070254857 2Alpha-Methyl-19-Nor-(20S)-1Alpha-Hydroxy-Bishomopregnacalciferol and Its Uses
10/2007
10/31/2007EP1848442A1 2-methylene-19-nor-(20s-24epi)-1alpha,25-dihydroxyvitamine-d2
10/25/2007US20070249568 17,20(E)-dehydro vitamin D analogs and their uses
10/25/2007US20070249567 2-Methylene-19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Its Uses
10/24/2007EP1846370A2 2-METHYLENE-19-NOR-1&agr;-HYDROXY-17-ENE-HOMOPREGNACALCIFEROL AND ITS USES
10/24/2007EP1846369A2 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses
10/18/2007WO2007118198A2 2-METHYLENE-1α,25-DIHYDROXY-19,21-DINORVITAMIN D3 ANALOGS AND USES THEREOF
10/18/2007WO2007117563A2 1.alpha.-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and use thereof
10/18/2007WO2007092721A3 Vitamin d analog: rak, methods and uses thereof
10/18/2007WO2007092720A3 Vitamin d analog: nel, methods and uses thereof
10/18/2007US20070244072 1a-Hydroxy-2-(3'-Hydroxypropylidene)-19-nor-vitamin D compounds and methods of making and treatment thereof
10/18/2007CA2648324A1 2-methylene-1.alpha.,25-dihydroxy-19,21-dinorvitamin d3 analogs and uses thereof
10/18/2007CA2648193A1 1.alpha.-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and use thereof
10/17/2007EP1844010A1 Isomerisation of pharmaceutical intermediates
10/11/2007US20070238706 2-Methylene-1Alpha,25-Dihydroxy-19,21-Dinorvitamin D3 Analogs and Uses Thereof
10/11/2007US20070238705 2-Methylene-1Alpha,25-Dihydroxy-18,19,21-Trinorvitamin D3 and Uses Thereof
10/11/2007US20070238704 2-Substituted-1Alpha,25-Dihydroxy-19,26,27-Trinor Vitamin D Analogs and Uses Thereof
10/11/2007US20070238703 1 alpha -hydroxy-2-[3'-hydroxypropylidene]-20-methyl-19, 24, 25, 26, 27-pentanorvitamin D3, used as an anticarcinogenic agent, for the treatment of skin disorders, autoimmune diseases, inflammatory diseases, renal osteodystrophy, and/or prevention of obesity
10/11/2007US20070238702 Metabolic bone disease; psoriasis; leukemia; colon, breast, prostate, skin, lung cancer; multiple sclerosis; lupus; diabetes mellitus; host versus graft reaction; rejection of organ transplants; an inflammatory disease selected from rheumatoid arthritis, asthma, psoriasis
10/11/2007US20070238701 2-Methylene-1alpha-Hydroxy-18,19,21-Trinorvitamin D3 Analogs and Uses Thereof
10/06/2007WO2008125901A2 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin d3 and uses thereof
10/06/2007CA2639585A1 2-methylene-1.alpha., 25-dihydroxy-18, 19, 21-trinorvitamin d3 and uses thereof
10/03/2007EP1838667A2 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses
10/03/2007EP1838666A1 Process for preparation of a pharmaceutical grade calcipotriol anhydrous
09/2007
09/27/2007US20070225513 2 beta -(3'-hydroxypropoxy)-5,7-cholestadiene-1 alpha ,3 beta -triol , purity
09/26/2007EP1268416B1 2-alkylidene-19-nor-vitamin d compounds and their therapeutic uses
09/20/2007WO2007105773A1 Process for production of indene derivative, and intermediate for production of the derivative
09/20/2007US20070215455 Isomerisation of pharmaceutical intermediates
09/19/2007EP1833485A2 Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof
09/13/2007US20070213546 (20R)-1 alpha ,25-dihydroxy-2-[3'-hydroxypropylidene]-19-norvitamin D3; high intestinal calcium transport activity; ability to mobilize calcium from bone; bone replacement surgeries, autoimmune diseases, multiple sclerosis, diabetes mellitus,lupus, antiproliferative agents
09/12/2007EP1831161A2 2-methylene-19-nor-(20r)-1-alpha-hydroxy-bishomopregnacalciferol
09/05/2007EP1829860A1 9,10-secopregnane derivative and medicine
09/05/2007EP1828115A2 2-methylene-19-nor-(20s)-1alpha-hydroxy-trishomopregnacalciferol
09/05/2007EP1828114A2 17,20(e)-dehydro vitamin d analogs and their uses
09/05/2007EP1828113A2 2-methylene-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and its uses
09/05/2007EP1827452A2 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol
08/2007
08/30/2007WO2007022433A3 SYNTHESIS OF 1α-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL
08/29/2007EP1824818A2 2ALFA-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1ALFA-HYDROXYVITAMIN D3 AND THEIR USES
08/16/2007US20070191317 (20R,25R)-2-Methylene-19,26-dinor-1 alpha ,25-dihydroxyvitamin D3, used for the treatment of psoriasis, leukemia, cancer, multiple sclerosis, lupus, diabetes, graft versus host disease, transplant rejection, inflammatory diseases, skin disorders, osteoporosis and rickets
08/16/2007US20070191316 2-Methylene-19,26-dinor-1 alpha ,25-dihydroxyvitamin D3; psoriasis; leukemia, cancer, multiple sclerosis; lupus; diabetes mellitus; host versus graft reaction; rejection of organ transplants; decrease the calcemic effect while retaining the ability to suppress parathyroid hormone
08/16/2007CA2637817A1 Vitamin d analog - nel, methods and uses thereof
08/16/2007CA2637302A1 Vitamin d analog-rak, methods and uses thereof
08/15/2007EP1817279A2 17,20(z)-dehydro vitamin d analogs and their uses
08/15/2007EP1817278A2 2-methylene-18,19-dinor-1alfa-hydroxy-homopregnacalciferol and its uses
08/09/2007WO2007006036A3 Hydroxylated forms of ergosterols and ergocalciferols, derivatives thereof, methods of production and uses thereof
08/08/2007EP1814847A1 Novel method for preparing 3-[5'-(3,4-bis-hydroxymethyl-benzyloxy)-2'- ethyl-2-propyl-biphenyl-4-yl]-penta-3-ol
08/07/2007US7253293 5Z,7E-3 beta ,11 alpha -dihydroxy-9,10-secopregna-5,7,10(19)trien-20-one; from enzymatically hydroxylating the vitamin D3-like compound
08/01/2007CN101010295A Crystalline forms of 1,24(S)-dihydroxy vitamin D2
07/2007
07/26/2007WO2007082533A1 Isomerisation of pharmaceutical intermediates
07/26/2007CA2646856A1 Isomerisation of pharmaceutical intermediates
07/25/2007EP1809599A1 Vitamin d3 analogues for the prevention and treatment of bone disorders
07/25/2007CN1328256C Method of preparig 1 alpha-hydroxy vitamin D or its analogue from 1 beta-hydroxy vitamin D or its analogue
07/24/2007US7247752 Stereoselectively reducing 2,6,6-trimethyl-2-cyclohexene-1,4-dione with an optically active chiral catalyst to form an optically active hydroxycyclohexenone, contacting the product with a reducing agent to form an optically active diol, and using the diol to form astaxanthin
07/18/2007CN101001835A Epimerisation of allylic alcohols
07/17/2007US7244719 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses
07/10/2007US7241752 17,20(E)-dehydro vitamin D analogs and their uses
07/10/2007US7241750 2-methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses
07/10/2007US7241748 Especially 17(Z)-1 alpha ,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3; arrests the proliferation of undifferentiated cells and induces their differentiation to monocytes; treating cancer, skin disorders, autoimmune disorders, inflammatory conditions, and renal osteodystrophy
06/2007
06/28/2007US20070149489 Preparation of paricalcitol
06/26/2007USRE39706 Crystalline form of a vitamin D analogue
06/26/2007US7235680 2-methylene-19-nor-(23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone and 2-methylene-19-nor-(23R)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone
06/26/2007US7235679 Crystals of a vitamin D derivative and a method for the preparation thereof
06/20/2007EP1797033A2 20-cycloalkyl,26,27-alkyl/haloalkyl vitamin d3 compounds and methods of use thereof
06/19/2007US7232810 Characterized by minimal bone calcium mobilization activity and relatively high intestinal calcium transport activity; used to treat renal osteodystrophy, osteoporosis, autoimmune diseases such as multiple sclerosis, cancer and psoriasis
06/14/2007US20070135395 Novel method for the preparation of intermediates useful for the synthesis fo vitamin d analogues
06/14/2007US20070135394 Process for the synthesis of vitamin d compounds and intermediates for the synthesis of the compounds
06/07/2007WO2007064011A1 Method for producing vitamin d derivative by using convergent method
06/07/2007WO2007063930A1 Method for producing vitamin d derivative utilizing photoreaction
06/07/2007US20070129558 Monohalogenovinyl vitamin d derivative compounds
05/2007
05/30/2007EP1789384A1 Epimerisation of allylic alcohols
05/22/2007CA2069084C 1.alpha.-hydroxy vitamin d4 and novel intermediates and analogues
05/08/2007US7214670 Administering to a post menopausal woman an effective amount of 2-methylene -19-nor-20(S)-1 alpha ,25-dihydroxyvitamin D3
05/01/2007US7211680 (5Z,7E,22E)-(1S,3R,24R)-25-phenyl-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol; treating hyperprolifierative diseases of the skin, tumor diseases and precancerous stages, auto-immune diseases, rejection reactions in the case of autologous, allogenic or xenogenic transplants, AIDS
05/01/2007US7211172 Irradiatiing a photosensitizer-free reaction mixture containing provitamin D with light energy having a wavelength of 254 nm followed by a second irradiation of the mixture with light energy having a wavelength of 313 nm .
04/2007
04/26/2007WO2006113990B1 LOW-CALCEMIC 16,23-DIENE 25-OXIME ANALOGS OF 1α ,25-DIHYDROXY VITAMIN D3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 ... 35